BEIGF · BeOne Medicines Ltd. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on BEIGF. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About BEIGF · BeOne Medicines AG
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
Live Quote
HOLD (score -2) · 12-1 mom 41.1% · RSI 0 · below_both · -13.2% from high
Targets blend Wall Street consensus (? analysts: low — / mean — / high —) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Stage produced output that could not be parsed as a valid JSON object. ~6h cooldown before retry.
{"symbol":"BEIGF","company":"BeOne Medicines AG (ADRs, listed as BEIGF representing 1/13th of ONC)","investigation_summary":"BEIGF is the OTC ADR quote for BeOne Medicines Ltd. (Nasdaq: ONC), a $29.6B global oncology company anchored by BRUKINSA (zanubrutinib). The investigation was triggered on an insider cluster signal, but upon detailed Form 4 review, all three June 16, 2026 filings (CEO John O
Investigation triggered by a cluster of 5 Form 4 filings within 14 days. After reading each filing in full, all five transactions are S-code (sell) executions — specifically mandatory tax-withholding sales pursuant to RSU vesting schedules for John Oyler (CEO), Xiaobin Wu (COO), Wang Lai (R&D Head), Lee Chan Henry (General Counsel), and Ball Titus B. (PAO). No open-market P-code purchases exist in the recent cluster, and zero option markets are available on this OTC-traded ADR (Nasdaq: ONC). The stock is technically weak (below both 20/50 DMAs; bearish MACD cross) from a ~25 high toward $21.94. Despite meaningful bullish catalysts — FDA accelerated approval of BEQALZI (sonrotoclax), Priority Review for TEVIMBRA + ZIIHERA in first-line HER2+ GEA, Q1 2026 earnings beat, multiple analyst price-target raises to $395-$420 — none translate into a structured trade because BEIGF has no listed options. The pipeline halts here.